Author argues ADTX is undervalued given new interim CEO Jeffrey Busch's track record and the pending Ignite Proteomics merger.
ADTX — LONG The author argues ADTX is undervalued at pennies relative to its true value because new interim CEO Jeffrey M. Busch has a strong track record running a billion-dollar market cap healthcare real estate company (GMRE/XRN) and holds presidential appointments. The pending merger with Ignite Proteomics Holdings (pubco) will create an entity holding $150 million worth of shares, which the author believes supports a valuation of at least $0.25-$0.50 per share despite 185 million shares outstanding. Busch has only been CEO for less than a month and is executing a restructuring. The main risk is the large share count and the speculative nature of the merger.
Buying in now when it’s worth Pennie’s compared to its true value. It will be holding $150 million worth of shares for this newly merged entity (pubco) Ignite Proteomics Holdings, Inc.
This Reddit post, published June 16, 2026, features u/Jazzlike_Rhubarb4639 discussing ADTX. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Jazzlike_Rhubarb4639 · Tickers: ADTX